What is the difference between adjuvant and neoadjuvant treatment for Non-Small Cell Lung Cancer

Adjuvant vs. Neoadjuvant Treatment for NSCLC

Great question—understanding the timing and purpose of these treatments is important for your care planning. Let me break down the key differences:

NEOADJUVANT THERAPY (Treatment Before Surgery)

Neoadjuvant therapy is systemic treatment (chemotherapy, immunotherapy, or both) given before surgery to shrink the tumor and treat any cancer cells that may have spread.

When it's used: According to NCCN Guidelines, neoadjuvant therapy is typically recommended for patients with:

• Tumors that are 4 centimeters or larger, OR
• Lung cancer that has spread to lymph nodes (node-positive disease)

What it includes: The NCCN Guidelines recommend neoadjuvant chemoimmunotherapy combinations such as:

• Nivolumab (Opdivo) + platinum-based chemotherapy (up to 4 cycles)
• Pembrolizumab (Keytruda) + platinum-based chemotherapy (4 cycles)
• Durvalumab + platinum-based chemotherapy (4 cycles)

The goal: Shrink the cancer before surgery to make it easier to remove completely and improve long-term survival.

---

ADJUVANT THERAPY (Treatment After Surgery)

Adjuvant therapy is systemic treatment given after surgery to eliminate any remaining cancer cells that may not be visible but could grow later.

When it's used: According to NCCN Guidelines, adjuvant therapy is considered for patients with:

• Completely resected tumors ≥4 cm, OR
• Node-positive disease (cancer spread to lymph nodes)

What it includes: Options depend on your specific biomarkers:

• For ALK-positive NSCLC: Alectinib (600 mg twice daily for 24 months)
• For EGFR-mutated NSCLC: Osimertinib (80 mg daily for 3 years)
• For PD-L1 positive (≥1%) without EGFR/ALK mutations: Atezolizumab or pembrolizumab for up to 1 year
• Standard chemotherapy: Platinum-based combinations if you didn't receive neoadjuvant therapy

The goal: Kill any remaining microscopic cancer cells after surgery to reduce the risk of recurrence.

---

Key Clinical Differences

| Aspect | Neoadjuvant | Adjuvant | |--------|-------------|----------| | Timing | Before surgery | After surgery | | Purpose | Shrink tumor; improve resectability | Eliminate remaining cells | | Surgery timing | Happens after treatment | Already completed | | Treatment duration | Usually 4 cycles (8-12 weeks) | Varies: 1-3 years depending on drug |

---

Why Choose One Over the Other?

According to NCCN Guidelines, if you're likely to need systemic therapy anyway, your oncologist may recommend neoadjuvant therapy instead of adjuvant therapy because:

1. Better tumor shrinkage - The NCCN Guidelines note that neoadjuvant nivolumab + chemotherapy showed a pathologic complete response (≤10% viable tumor) in 36.9% of patients versus only 8.9% with chemotherapy alone
2. Easier surgery - A smaller tumor may be easier to remove completely
3. Earlier treatment - You start cancer-fighting treatment right away rather than waiting for surgery to heal
4. Better outcomes - Clinical trials show improved survival with neoadjuvant approaches

---

Important Considerations

⚠️ Not everyone is a candidate for immunotherapy-based neoadjuvant treatment. According to NCCN Guidelines, your doctor will NOT prescribe chemoimmunotherapy if:

• You have an active autoimmune disease
• You're taking medications that suppress your immune system
• You have EGFR mutations or ALK rearrangements (these respond better to targeted therapy than immunotherapy)

---

Questions to Ask Your Oncologist

1. Based on my tumor size and lymph node involvement, am I a candidate for neoadjuvant therapy?
2. Have I been tested for EGFR mutations, ALK rearrangements, and PD-L1 status? (These results guide which treatment is best)
3. What are the pros and cons of neoadjuvant vs. adjuvant therapy for my specific situation?
4. If I receive neoadjuvant therapy, what happens if the tumor doesn't shrink as expected?
5. What side effects should I expect, and how will they be managed?

---

Sources:

• NCCN Guidelines for Non-Small Cell Lung Cancer, Version 8.2025 (Perioperative Systemic Therapy section)
• NCCN Guidelines for Patients: Early and Locally Advanced Non-Small Cell Lung Cancer, 2024

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.